コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ell migration toward chemokines (TARC/CCL17, IP-10).
2 of chemoattractants for monocytes (MCP-1 and IP-10).
3 (CXCL-10)/IFN-gamma-inducible 10-kD protein (IP-10).
4 ng beta 1 interferon (IFN-beta1) and CXCL10 (IP-10).
5 cal upregulation of TLR7-mediated cytokines (IP-10).
6 luding chemokines MIP-1alpha, MIP-1beta, and IP-10).
7 n FGF-Basic, IL-15, IL-6, IL-28A, ENA-78 and IP-10.
8 h low IP-10 had 64% SVR versus 24% with high IP-10.
9 (IL-1alpha, IL-8, IL-12(p70)) and increased IP-10.
10 GF, FGF-2, IL-8, TIMP-1, TIMP-2, GM-CSF, and IP-10.
11 reduced expression of iNOS, IL-6, MCP-1 and IP-10.
12 g the transendothelial migration response to IP-10.
13 class II and secretion of IL-8, RANTES, and IP-10.
14 th the "No Infect and No ACR" group (CXCL10 [IP-10]: 107.0 vs. 31.9 pg/mL [P=0.001] and IL-16: 472.1
15 high plasma levels of CXCL10 (also known as IP-10), a chemokine that directs T cells to sites of inf
17 comparable amounts of TNFalpha, IL-12p40 and IP-10 after infection with H3N2, in marked contrast to d
18 s (IL-6, CD163, IL-10, LBP, IL-2, MCP-1, and IP-10), all with ORs for the 3(rd) versus 1(st) tertile
21 ed alanine aminotransferase and pretreatment IP-10 and between the presence of cirrhosis and elevated
22 MACs might be mediated via downregulation of IP-10 and changes in ED:EI by MAC regulation of eNOS in
26 that the relative balance between levels of IP-10 and eotaxin is critical in regulating the neovascu
30 nificantly lower dNK cell numbers and higher IP-10 and I-TAC levels versus gestational age-matched co
31 g a correlation with the IFN gene signature (IP-10 and I-TAC), and this score was compared between 26
35 ynergy, production levels of CXCR3 cytokines IP-10 and MIG, depend non-linearly on both IFNgamma and
39 gether contributing to the downregulation of IP-10 and other Th1 cell-recruiting chemokines (e.g., CX
42 sfusion need; IL-2R, IL-8, and leukocytosis; IP-10 and thrombocytopenia; HGF, MIG, IL-1RA, and marked
43 ) and plasmacytoid DCs (pDCs), production of IP-10 and type-I IFN, and expression of type-I IFN-relat
46 nes, including GM-CSF, IFN-alpha2, IL-12p70, IP-10 and VEGF, during both acute and chronic stages of
50 and inhibition of IFN-gamma-induced CXCL10 (IP-10) and FcgammaRI (CD64) indicated that inhibition by
53 at therapeutic strategies to inhibit CXCL10 (IP-10) and or its cognate receptor, CXCR3, warrant inves
54 er levels of IFN-gamma-inducible protein-10 (IP-10) and tumor necrosis factor-related apoptosis-induc
56 reased CSF levels of CCL3, CCL5, and CXCL10 (IP-10), and decreased activation of both resident CNS an
57 kin 10, interferon gamma-induced protein 10 (IP-10), and hepatocyte growth factor differentiated betw
58 otein-1, interferon-gamma-inducible protein (IP-10), and macrophage inflammatory protein-1delta) were
59 CCL4 (MIP-1beta), CCL5 (RANTES), and CXCL10 (IP-10), and promoting chemotaxis of macrophages and CD4(
60 M-1), interferon-gamma-inducible protein 10 (IP-10), and the signaling intermediates Janus kinase 1,
61 induced massive upregulation of MIP-1alpha, IP-10, and IFN-alpha in normal blood mononuclear cells.
65 nchial epithelial cells induces apical IL-8, IP-10, and MCP-1 secretion independent of infection, sug
67 ely to have higher peak levels of IFN-gamma, IP-10, and MIG after vaccination than were revaccinated
68 ines and chemokines, including IL-6, RANTES, IP-10, and MIP-3a, which were regulated by NFkappaB sign
69 (growth-related oncogene alpha [GRO-alpha], IP-10, and monokine induced by gamma interferon [MIG]),
72 IS (not on CTC) IL-6, IL-8, IL-12p40, IL-18, IP-10, and TNF increased during 2 weeks (P </= .04) of A
73 a], 10-kDa gamma interferon-induced protein [IP-10]) and proinflammatory (interleukin 1 receptor anta
74 n [IL]-6, IL-8, IL-15, IL-16, IL-17, CXCL10 [IP-10], and MCP-1 [CCL2]) in BAL samples (n=233) from pa
75 ls of interferon-gamma-inducible protein-10 (IP-10) are predictive of treatment-induced clearance in
76 clampsia compared with controls, identifying IP-10 as a novel, robust early predictor of preeclampsia
77 letokine expression in beta-cells and reveal IP-10 as a primary therapeutic target to prevent beta-ce
78 ther studies should evaluate the benefits of IP-10 as a triage approach to monitor ART in resource-li
79 more likely to have a measurable decline in IP-10 at day 7 than clinically diagnosed cases (48/77 (6
80 Logistic regression was used to build an IP-10-based model able to identify individuals with VL >
81 ficantly higher levels of interleukin 18 and IP-10 but lower levels of hepatocyte growth factor than
82 expressed by basal keratinocytes and CXCL10/IP-10 by keratinocytes and endothelial cells during woun
84 tes/macrophages, and found that induction of IP-10 by MRP8/MRP14 required Toll-like receptor 4 and TR
85 presence of S. aureus The downregulation of IP-10 by S. aureus was mediated by components of its cel
87 uction in the serum concentration of CXCL10 (IP-10), CCL22 (MDC), CCL17 (TARC), CCL-2 (MCP-1) and CCL
88 nasal aspirate IFN-gamma, CXCL8/IL-8, CXCL10/IP-10, CCL5/RANTES, CCL11/eotaxin-1, CCL2/MCP-1, CCL4/MI
89 nes and receptors (IL-22, CCL27, MIP-1alpha, IP-10, CCR4, CCR5, and CXCR3), immune dysfunctional rece
92 nterferon-inducible cytokines OAS and CXCL10/IP-10 compared with control mice treated with fluticason
94 rmed that donor islet-specific expression of IP-10 contributed to islet inflammation and loss of beta
96 erved in stromal cell-derived factor-1alpha, IP-10, cutaneous T-cell-attracting chemokine, monokine i
97 ed levels of IFN-gamma-inducible protein 10 (IP-10/CXCL), IL-8, and MCP-1, all of which have been rep
98 f interleukin 12, IFN-gamma, and chemokines (IP-10/CXCL-10, MCP-1/CCL-2, MIP-1alpha/CCL-3, RANTES/CCL
99 nduce the expression of the T-cell chemokine IP-10 (CXCL10) from neutrophils, peripheral blood mononu
100 and the IFN-inducible CXCR3 chemokine ligand IP-10 (CXCL10) was recently found to be the only serum b
105 .001), IL-6 (P<0.001), IL-8/CXCL8 (P<0.001), IP-10/CXCL10 (P<0.05), MCP-1/CCL2 (P<0.05), macrophage i
108 1RN, CASP1, IL18RAP), and IFN-induced (AIM2, IP-10/CXCL10) genes were significantly overexpressed, bu
109 ytokine interferon-gamma-induced protein 10 (IP-10/CXCL10) was among the highest released, and high l
110 okine targets in skeletal muscle (IL-1ra and IP-10/CXCL10) were identified from a cytokine array.
111 le chemokines IFNgamma-inducible protein 10 (IP-10/CXCL10), IFN-inducible T cell alpha chemoattractan
112 eron-gamma (IFN-gamma)-inducible protein 10 (IP-10/CXCL10), monokine induced by IFN-gamma (Mig/CXCL9)
114 NA encoding TSLP, TARC/CCL17, MDC/CCL22, and IP-10/CXCL10, but not I-TAC/CXCL11 and I-309/CCL1, were
115 MDC/CCL22, I-309/CCL1), and Th1-attracting (IP-10/CXCL10, I-TAC/CXCL11) chemokines in the bronchial
116 y affected by GSK3beta inactivation included IP-10/CXCL10, MCP-1/CCL2, IL-8/CXCL8, RANTES/CCL5, and G
117 s of chemokines for activated T lymphocytes (IP-10/CXCL10, MIG/CXCL9), G-CSF, and proinflammatory cyt
118 nt ELR-devoid CXC chemokines (ie, PF4/CXCL4, IP-10/CXCL10, MIG/CXCL9, and IP-9/CXCL11), we sought to
119 ophage inflammatory protein 2 (MIP-2)/CXCL2, IP-10/CXCL10, MIP-1alpha/CCL3, granulocyte colony-stimul
120 ated negatively with serum concentrations of IP-10/CXCL10, whereas CD4(+)/HLA-DR(+) T lymphocyte coun
121 lloproteinase 9 (1.30), the interaction term IP-10/CXCL10xwomen (0.69), and the interaction term thro
122 teins CD3, CD4, CD8, CTLA4, Foxp3, chemokine IP-10, cytotoxic perforin and granzyme B, and BKV VP1 mR
130 ed a novel signaling mechanism that controls IP-10 expression in monocytes/macrophages by MRP8/MRP14,
133 -gamma), and IFN-gamma-inducible protein 10 (IP-10) from the arrays for further investigation and ass
134 and p300 histone acetyltransferase with the IP-10 gene required p38 and c-Jun N-terminal kinase mito
135 In vitro studies showed induction of the IP-10 gene was mediated by calcineurin-dependent NFAT si
136 ma (GM, 5.44 vs 23.41 pg/ml; p = 0.009), and IP-10 (GM, 29.43 vs 281.7 pg/ml; p = 0.007) responses fo
137 , IL-6; Interferon-gamma-induced Protein 10, IP-10; Granulocyte-stimulating factor, G-CSF) in the med
140 interferon [IFN] gamma-inducible protein 10 [IP-10]) have been associated with hepatic fibrosis in pr
142 taining of first trimester decidua localized IP-10, I-TAC, IFN-gammaR1, and -R2 to vimentin-positive
143 CCL11 (Eotaxin-1), CXCL1 (GROalpha), CXCL10 (IP-10), IFN-gamma, IL-4, IL-5, IL-7, IL-12p70, IL-13, IL
144 mokines and cytokines CCL5 (RANTES), CXCL10 (IP-10), IL-1alpha, IL-1beta, and PGE(2), which have prev
148 ntial role for proinflammatory mediators and IP-10 in combination with the vaginal-health-score as pr
149 he mechanisms by which MRP8/MRP14 stimulates IP-10 in monocytes/macrophages, and found that induction
155 CXCL10 (interferon gamma-induced protein 10, IP-10) increase in plasma and the peritoneal cavity afte
156 In contrast, overexpression of RANTES or IP-10 increased RABV pathogenicity by causing neurologic
160 K but weak JNK activation, resulting in high IP-10 (interferon-inducible protein 10), tumor necrosis
161 nic (TNFalpha [tumor necrosis factor alpha], IP-10 [interferon gamma-induced protein 10]), and proinf
162 P-2), interferon gamma inducible protein-10 (IP-10), interferon gamma (IFN-gamma), tumor necrosis fac
163 feron (IFN)-gamma, IFN-inducible protein-10 (IP-10), interleukin (IL)-6, and tissue inhibitor of meta
164 nvaccinated individuals, induced protein 10 (IP-10), interleukin 10 (IL-10), macrophage inflammatory
165 (VEGF), interferon gamma-induced protein 10 (IP-10), interleukin-8 (IL-8), epidermal growth factor (E
168 IP-10 levels mirror HCV RNA, suggesting that IP-10 is an indicator of innate immune viral recognition
171 as interferon-gamma-inducible 10-kd protein [IP-10]) is a chemokine that potentially plays a role in
172 interferon (IFN-gamma)-stimulated release of IP-10, ITAC (CXCL11), and Mig (CXCL9) from epithelial ce
174 for previously described TB markers, such as IP-10, LBP, FCG3B, and TSP4, and for many novel proteins
176 ontaneous clearance (83% of those who had an IP-10 level <540 pg/mL and 32% who had an IP-10 level >5
178 lysis, factors independently associated with IP-10 levels >/=150 pg/mL (median level) included HCV RN
182 Here we investigate the early response in IP-10 levels (between day 0 and day 7 of TB therapy) to
183 te HCV detection and the association between IP-10 levels and spontaneous clearance were assessed in
185 onfirmed cases were more likely to have high IP-10 levels at D0 and had a steeper decline than clinic
186 resent study, factors associated with plasma IP-10 levels at the time of acute HCV detection and the
187 earance had significantly higher mean plasma IP-10 levels at the time of acute HCV detection than tho
188 nfirms the association between a decrease in IP-10 levels during the first week of treatment and a ba
192 ), whereas during week 2 the mean decline in IP-10 levels in treatment-naive patients (-14%) was sign
200 We assessed the combination of pretreatment IP-10 levels with IL28B genotype as predictors of treatm
202 Patients with acute HCV and high baseline IP-10 levels, particularly >380 pg/mL, should be conside
204 Plasma interferon-gamma-induced protein 10 (IP-10) levels declined significantly upon dosing with RG
205 easured interferon gamma-induced protein 10 (IP-10) levels in 428 patients at baseline, week 1, and w
207 ted in reduced milk levels of the chemokines IP-10, MCP-1, MCP-3, MCP-5 and MIP-1beta, which in turn
209 genotype is combined with pretreatment serum IP-10 measurement, the predictive value for discriminati
214 f MDX-1100, a fully human, anti-CXCL10 (anti-IP-10) monoclonal antibody, in RA patients whose disease
215 ma levels of IFN-gamma-inducible protein 10 (IP-10), monocyte chemoattractant protein 1 (MCP-1), macr
216 nterferon-gamma-inducible protein of 10 kDa (IP-10), monocyte chemoattractant protein-1 (MCP-1), tumo
217 n 8 (IL-8), interferon-inducible protein 10 (IP-10), monocyte chemotactic protein 1 (MCP-1), and RANT
218 IL-8, interferon-gamma inducible protein-10 [IP-10], monocyte chemoattractant protein-1, macrophage i
219 actor (HGF), IFN-gamma-inducible protein 10 (IP-10), monokine induced by IFN-gamma (MIG), monocyte ch
220 A-normalized measures of CD3epsilon mRNA and IP-10 mRNA and 18S rRNA that is diagnostic and predictiv
221 A molecular signature of CD3epsilon mRNA, IP-10 mRNA, and 18S rRNA levels in urinary cells appears
222 of IL28B and IFN-gamma-inducible protein 10 (IP-10) mRNA relies on TT/-G, but not rs12979860, making
223 on mRNA and interferon-inducible protein 10 (IP-10) mRNA, and 18S rRNA discriminated between biopsy s
226 METHODS AND We studied cardiac repair in IP-10-null and wild-type (WT) mice undergoing reperfused
229 CXCR3 ligands, CXCL11/IP-9/I-TAC and CXCL10/IP-10, on the EGF- and VEGF-induced redistribution of m-
230 high level of interferon-induced protein 10 (IP-10 or CXCL10) and hepatitis B surface and e antigens
235 P < .001), IL-8 (P < .001), IL-10 (P = .01), IP-10 (P = .0001), MDC (P < .001), MIP-1alpha, (P < .001
237 01), IL-12 (P < .001), IL-15 (P = .001), and IP-10 (P = .003) were independently predictive of inferi
238 ), IL-6 (P = 0.0396), IL-8 (P = 0.0169), and IP-10 (P = 0.0045) secretion during in vitro stimulation
240 a and suggest that the CXCR3 ligands Mig and IP-10 play distinct, nonredundant roles in the pathogene
241 ls of interferon gamma inducible protein 10 (IP-10) predict outcomes of antiviral therapy in patients
243 n increased gamma interferon (IFN-gamma) and IP-10 production within the septic peritoneum together w
244 lower IL-6 release while maintaining higher IP-10 production, skewing toward the type I interferon p
246 no NELF or polymerase is detectible near the IP-10 promoter before induction, and LPS-dependent polym
249 phage inflammatory protein 1alpha/CCL-3, and IP-10), reactive oxygen species (ROS), and nitric oxide,
251 ed vFLIP-induced expression of the chemokine IP-10, reduced vFLIP-induced cell proliferation and incr
253 nd IFN-gamma-inducible protein 10 (CXCL10 or IP-10) remained statistically significant in the multiva
257 d individuals had earlier peaks in IL-10 and IP-10 responses that occurred at much lower viral loads
258 pression by MACs (p<0.0006), and blockade of IP-10 restored the angiogenic capacity of MACs from pati
260 (CXCL9) from epithelial cells and inhibited IP-10 secretion in a mixed infection with the otherwise
261 expression and suppressed rhinovirus-induced IP-10 secretion, which was associated with increased vir
262 UA and OA (25 muM) reduced the synthesis of IP-10; sICAM-1, IL-23 and GROalpha were slightly repress
265 s was associated with the release of CXCL10 (IP-10), suggesting that this adjuvant formulation may ha
266 uced the release of IL-6, IL-8, TNFalpha and IP-10, suggesting that NS1 protein of Udorn does not (ef
271 perating characteristic analyses showed that IP-10, TNF-alpha, and IL-2 responses achieved high sensi
272 with siRNA directed against TNF-alpha, KC or IP-10 to mice suffering from dextran sulfate sodium (DSS
273 IFN-alpha, IFN-beta, IFN-gamma, IFN-lambda1, IP-10, TRAIL), cell recruiting (G-CSF, IL-1beta, IL-8, M
275 IFN-gamma, interferon-inducible protein-10 (IP-10), tumor necrosis factor (TNF)-alpha, IL-1ra, IL-2,
276 CTC had lower interferon gamma (IFN-gamma), IP-10, tumor necrosis factor (TNF), interleukin (IL)-6,
280 mparable cytokine expression, the absence of IP-10 was associated with marked alterations in the cell
285 operating characteristic analysis, 540 pg/mL IP-10 was set as the cutoff for patients most likely to
286 ent on CXCR3 signaling, and the CXCR3 ligand IP-10 was sufficient to recruit monocytes to the adventi
288 n addition, interferon-inducible protein 10 (IP-10) was identified as playing an important role in Ni
289 e Th1-associated chemokines RANTES, MIG, and IP-10 were each elevated significantly in the livers of
290 ory protein 1alpha (MIP-1alpha), RANTES, and IP-10 were individually cloned into the genome of attenu
291 rase chain reaction; serum concentrations of IP-10 were measured by enzyme-linked immunosorbent assay
292 Dose-related increases in nasal and serum IP-10 were observed 24 hours after doses 1 and 8 (>95% c
293 te chemoattractant protein 1, TNF-alpha, and IP-10 were observed in ZIKV-infected pregnant women carr
294 e transcripts for TLR7, RelA, IFN-gamma, and IP-10 were significantly downregulated between 2- and 3-
297 Nasal and serum IFN-inducible protein 10 (IP-10) were measured after doses 1 and 8, then 1 (follow
298 ls of interferon-gamma-inducible protein 10 (IP-10) were quantified by enzyme-linked immunosorbent as
299 Finally, we demonstrated that the chemokine IP-10, which is induced by IFN-alpha and VRP-GFP, is dir
300 60 and rs8099917, along with serum levels of IP-10, with outcomes of patients with acute hepatitis C
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。